当前位置: 首页 >> 检索结果
4781. Ultrasound-Guided Optogenetic Gene Delivery for Shock-Free Ventricular Rhythm Restoration.
作者: Emile C A Nyns.;Tianyi Jin.;Cindy I Bart.;Wilhelmina H Bax.;Guoqi Zhang.;René H Poelma.;Antoine A F de Vries.;Daniël A Pijnappels.
来源: Circ Arrhythm Electrophysiol. 2022年15卷1期e009886页 4782. Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study.
作者: Shelby D Reed.;Jui-Chen Yang.;Timothy Rickert.;F Reed Johnson.;Juan Marcos Gonzalez.;Robert J Mentz.;Mitchell W Krucoff.;Sreekanth Vemulapalli.;Philip B Adamson.;David J Gebben.;Liliana Rincon-Gonzalez.;Anindita Saha.;Daniel Schaber.;Kenneth M Stein.;Michelle E Tarver.;Dean Bruhn-Ding.
来源: Circ Heart Fail. 2022年15卷1期e008797页
Regulatory and clinical decisions involving health technologies require judgements about relative importance of their expected benefits and risks. We sought to quantify heart-failure patients' acceptance of therapeutic risks in exchange for improved effectiveness with implantable devices.
4783. Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload.
作者: Jessie van Wezenbeek.;Azar Kianzad.;Arno van de Bovenkamp.;Jeroen Wessels.;Sophia A Mouratoglou.;Natalia J Braams.;Samara M A Jansen.;Eva Meulblok.;Lilian J Meijboom.;J Tim Marcus.;Anton Vonk Noordegraaf.;Marie José Goumans.;Harm Jan Bogaard.;M Louis Handoko.;Frances S de Man.
来源: Circ Heart Fail. 2022年15卷2期e008726页
Heart failure with preserved ejection fraction (HFpEF) is a prevalent disorder for which no effective treatment yet exists. Pulmonary hypertension (PH) and right atrial (RA) and ventricular (RV) dysfunction are frequently observed. The question remains whether the PH with the associated RV/RA dysfunction in HFpEF are markers of disease severity.
4785. Rotational Activation Pattern During Functional Substrate Mapping: Novel Target for Catheter Ablation of Scar-Related Ventricular Tachycardia.
作者: Masayuki Hattori.;Yuki Komatsu.;Qasim J Naeemah.;Yuichi Hanaki.;Noboru Ichihara.;Chihiro Ota.;Takeshi Machino.;Kenji Kuroki.;Hiro Yamasaki.;Miyako Igarashi.;Kazutaka Aonuma.;Akihiko Nogami.;Masaki Ieda.
来源: Circ Arrhythm Electrophysiol. 2022年15卷1期e010308页
Recent advancements in a 3-dimensional mapping system allow for the assessment of detailed conduction properties during sinus rhythm and thus the establishment of a strategy targeting functionally abnormal regions in scar-related ventricular tachycardia (VT). We hypothesized that a rotational activation pattern (RAP) observed in maps during baseline rhythm was associated with the critical location of VT.
4786. Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction.
作者: Gijs van Woerden.;Dirk J van Veldhuisen.;Olivier C Manintveld.;Vanessa P M van Empel.;Tineke P Willems.;Rudolf A de Boer.;Michiel Rienstra.;B Daan Westenbrink.;Thomas M Gorter.
来源: Circ Heart Fail. 2022年15卷3期e009238页
Epicardial adipose tissue (EAT) accumulation is thought to play a role in the pathophysiology of heart failure (HF) with mid-range and preserved ejection fraction, but its effect on outcome is unknown. We evaluated the prognostic value of EAT volume measured with cardiac magnetic resonance in patients with HF with mid-range ejection fraction and HF with preserved ejection fraction.
4788. Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.
作者: Tristram D Bahnson.;Anna Giczewska.;Daniel B Mark.;Andrea M Russo.;Kristi H Monahan.;Hussein R Al-Khalidi.;Adam P Silverstein.;Jeanne E Poole.;Kerry L Lee.;Douglas L Packer.; .
来源: Circulation. 2022年145卷11期796-804页
Observational data suggest that catheter ablation may be safe and effective to treat younger and older patients with atrial fibrillation. No large, randomized trial has examined this issue. This report describes outcomes according to age at entry in the CABANA trial (Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation).
4789. Percutaneous Coronary Intervention Following Diagnostic Angiography by Noninterventional Versus Interventional Cardiologists: Insights From the CathPCI Registry.
作者: Fabio V Lima.;Pratik Manandhar.;Daniel Wojdyla.;Tracy Wang.;Herbert D Aronow.;Vishnu Kadiyala.;E Hope Weissler.;Nidhi Madan.;Ian C Gilchrist.;Cindy Grines.;J Dawn Abbott.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011086页
There are limited contemporary, national data describing diagnostic cardiac catheterization with subsequent percutaneous coronary intervention (ad hoc percutaneous coronary intervention [PCI]) performed by an invasive-diagnostic and interventional (Dx/IC) operator team versus solo interventional operator (solo-IC). Using the CathPCI Registry, this study aimed at analyzing trends and outcomes in ad hoc PCI among Dx/IC versus solo-IC operators.
4790. Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study.
作者: Andrew M Glazer.;Giovanni Davogustto.;Christian M Shaffer.;Carlos G Vanoye.;Reshma R Desai.;Eric H Farber-Eger.;Ozan Dikilitas.;Ning Shang.;Jennifer A Pacheco.;Tao Yang.;Ayesha Muhammad.;Jonathan D Mosley.;Sara L Van Driest.;Quinn S Wells.;Lauren Lee Shaffer.;Olivia R Kalash.;Yuko Wada.;Harris T Bland.;Zachary T Yoneda.;Devyn W Mitchell.;Brett M Kroncke.;Iftikhar J Kullo.;Gail P Jarvik.;Adam S Gordon.;Eric B Larson.;Teri A Manolio.;Tooraj Mirshahi.;Jonathan Z Luo.;Daniel Schaid.;Bahram Namjou.;Tarek Alsaied.;Rajbir Singh.;Ashutosh Singhal.;Cong Liu.;Chunhua Weng.;George Hripcsak.;James D Ralston.;Elizabeth M McNally.;Wendy K Chung.;David S Carrell.;Kathleen A Leppig.;Hakon Hakonarson.;Patrick Sleiman.;Sunghwan Sohn.;Joseph Glessner.; .;Joshua Denny.;Wei-Qi Wei.;Alfred L George.;M Benjamin Shoemaker.;Dan M Roden.
来源: Circulation. 2022年145卷12期877-891页
Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability.
4791. Impact of Interdisciplinary System-Wide Limb Salvage Advisory Council on Lower Extremity Major Amputation.
作者: Mehdi H Shishehbor.;Tarek A Hammad.;Tonia J Rhone.;Ahmad Younes.;Norman Kumins.;Abdullah Abdullah.;Jun Li.;Karem Harth.;Teresa L Carman.;Heather L Gornik.;Peter J Pronovost.;Vikram S Kashyap.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011306页 4792. Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial.
作者: Thomas K Jones.;Doff B McElhinney.;Julie A Vincent.;William E Hellenbrand.;John P Cheatham.;Darren P Berman.;Evan M Zahn.;Danyal M Khan.;John F Rhodes.;Shicheng Weng.;Lisa J Bergersen.
来源: Circ Cardiovasc Interv. 2022年15卷1期e010852页
The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reducing the lifetime burden of surgery for patients with complex congenital heart disease.
4795. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
作者: Perry Elliott.;Brian M Drachman.;Stephen S Gottlieb.;James E Hoffman.;Scott L Hummel.;Daniel J Lenihan.;Ben Ebede.;Balarama Gundapaneni.;Benjamin Li.;Marla B Sultan.;Sanjiv J Shah.
来源: Circ Heart Fail. 2022年15卷1期e008193页
Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
4798. Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility.
作者: Sasha Z Prisco.;Lynn M Hartweck.;Lauren Rose.;Patricia D A Lima.;Thenappan Thenappan.;Stephen L Archer.;Kurt W Prins.
来源: Circ Heart Fail. 2022年15卷1期e008574页
Right ventricular dysfunction (RVD) is the leading cause of death in pulmonary arterial hypertension (PAH), but no RV-specific therapy exists. We showed microtubule-mediated junctophilin-2 dysregulation (MT-JPH2 pathway) causes t-tubule disruption and RVD in rodent PAH, but the druggable regulators of this critical pathway are unknown. GP130 (glycoprotein 130) activation induces cardiomyocyte microtubule remodeling in vitro; however, the effects of GP130 signaling on the MT-JPH2 pathway and RVD resulting from PAH are undefined.
4799. PRDM16 Is a Compact Myocardium-Enriched Transcription Factor Required to Maintain Compact Myocardial Cardiomyocyte Identity in Left Ventricle.
作者: Tongbin Wu.;Zhengyu Liang.;Zengming Zhang.;Canzhao Liu.;Lunfeng Zhang.;Yusu Gu.;Kirk L Peterson.;Sylvia M Evans.;Xiang-Dong Fu.;Ju Chen.
来源: Circulation. 2022年145卷8期586-602页
Left ventricular noncompaction cardiomyopathy (LVNC) was discovered half a century ago as a cardiomyopathy with excessive trabeculation and a thin ventricular wall. In the decades since, numerous studies have demonstrated that LVNC primarily has an effect on left ventricles (LVs) and is often associated with LV dilation and dysfunction. However, in part because of the lack of suitable mouse models that faithfully mirror the selective LV vulnerability in patients, mechanisms underlying the susceptibility of LVs to dilation and dysfunction in LVNC remain unknown. Genetic studies have revealed that deletions and mutations in PRDM16 (PR domain-containing 16) cause LVNC, but previous conditional Prdm16 knockout mouse models do not mirror the LVNC phenotype in patients, and the underlying molecular mechanisms by which PRDM16 deficiency causes LVNC are still unclear.
4800. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
作者: Matthew A Cavender.;Robert A Harrington.;Gregg W Stone.;Ph Gabriel Steg.;C Michael Gibson.;Christian W Hamm.;Matthew J Price.;Renato D Lopes.;Sergio Leonardi.;Efthymios N Deliargyris.;Jayne Prats.;Kenneth W Mahaffey.;Harvey D White.;Deepak L Bhatt.; .
来源: Circ Cardiovasc Interv. 2022年15卷1期e010390页
Thrombotic events are reduced with cangrelor, an intravenous P2Y12 inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
|